EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics

Samuel J Modlin, Mikael Mansjö, Jim Werngren, Chidera M Ejike, Sven E Hoffner, Faramarz Valafar

Drug Resistance Updates · 2023

DOI: 10.1016/j.drup.2023.100959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2023. Verfasst von Samuel J Modlin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here, we describe a clinical case of pyrazinamide-resistant (PZA-R) tuberculosis (TB) reported as PZA-susceptible (PZA-S) by common molecular diagnostics. Phenotypic susceptibility testing (pDST) indicated PZA-R TB. Targeted Sanger sequencing reported wild-type PncA, indicating PZA-S TB. Whole Genome Sequencing (WGS) by PacBio and IonTorrent both detected deletion of a large portion of pncA, indicating PZA-R. Importantly, both WGS methods showed deletion of part of the primer region targeted by Sanger sequencing. Repeating Sanger sequencing from a culture in presence of PZA returned no result, revealing that 1) two minority susceptible subpopulations had vanished, 2) the PZA-R majority subpopulation harboring the pncA deletion could not be amplified by Sanger primers, and was thus obscured by amplification process. This case demonstrates how a small susceptible subpopulation can entirely obscure majority resistant populations from targeted molecular diagnostics and falsely imply homogenous susceptibility, leading to incorrect diagnosis. To our knowledge, this is the first report of a minority susceptible subpopulation masking a majority resistant population, causing targeted molecular diagnostics to call false susceptibility. The consequence of such genomic events is not limited to PZA. This phenomenon can impact molecular diagnostics' sensitivity whenever the resistance-conferring mutation is not fully within primer-targeted regions. This can be caused by structural changes of genomic context with phenotypic consequence as we report here, or by uncommon mechanisms of resistance. Such false susceptibility calls promote suboptimal treatment and spread of strains that challenge targeted molecular diagnostics. This motivates development of molecular diagnostics unreliant on primer conservation, and impels frequent WGS surveillance for variants that evade prevailing molecular diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansPyrazinamideAntitubercular AgentsPathology, MolecularAmidohydrolasesMicrobial Sensitivity TestsMutation

Stichwörter der Autor:innen

HeteroresistanceMolecular diagnosticsPyrazinamideTuberculosis

Substanzen

PyrazinamideAntitubercular AgentsAmidohydrolases

Autor:innen und Institutionen

  • Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA, USA.
  • Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
  • Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA, USA; Department of Global Public Health, Karolinska Institute, Stockholm, Swed…
  • Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA, USA. Electronic address: faramarz@sdsu.edu.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Modlin, S. J., Mansjö, M., Werngren, J., Ejike, C. M., Hoffner, S. E., & Valafar, F. (2023). Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2023.100959

Vancouver

Modlin SJ, Mansjö M, Werngren J, Ejike CM, Hoffner SE, Valafar F. Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics. Drug Resistance Updates. 2023. doi:10.1016/j.drup.2023.100959

BibTeX
@article{Modlin2023,
  author = {Modlin, Samuel J and Mansjö, Mikael and Werngren, Jim and Ejike, Chidera M and Hoffner, Sven E and Valafar, Faramarz},
  title = {Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics},
  journal = {Drug Resistance Updates},
  year = {2023},
  doi = {10.1016/j.drup.2023.100959}
}
Kostenlos starten →